De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Aditxt Beheer

Beheer criteriumcontroles 3/4

De CEO Aditxt's is Amro Albanna, benoemd in Jan2017, heeft een ambtstermijn van 7.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 519.23K, bestaande uit 83.2% salaris en 16.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.007% van de aandelen van het bedrijf, ter waarde $ 40.61. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 5.8 jaar.

Belangrijke informatie

Amro Albanna

Algemeen directeur

US$519.2k

Totale compensatie

Percentage CEO-salaris	83.2%
Dienstverband CEO	7.8yrs
Eigendom CEO	0.007%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

Aditxt gains on regaining compliance with Nasdaq listing requirements

Sep 29

Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split

Sep 13

Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate

Jul 08

Analyse CEO-vergoeding

Hoe is Amro Albanna's beloning veranderd ten opzichte van Aditxt's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$43m
Mar 31 2024	n/a	n/a	-US$41m
Dec 31 2023	US$519k	US$432k	-US$33m
Sep 30 2023	n/a	n/a	-US$30m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$500k	US$500k	-US$28m
Sep 30 2022	n/a	n/a	-US$43m
Jun 30 2022	n/a	n/a	-US$46m
Mar 31 2022	n/a	n/a	-US$46m
Dec 31 2021	US$2m	US$280k	-US$46m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$20m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$252k	US$252k	-US$9m
Sep 30 2020	n/a	n/a	-US$5m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$2m	US$252k	-US$6m
Sep 30 2019	n/a	n/a	-US$5m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$5m
Dec 31 2018	US$180k	US$180k	-US$6m
Dec 31 2017	US$198k	US$51k	-US$852k

Compensatie versus markt: De totale vergoeding ($USD 519.23K ) Amro } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 667.78K ).

Compensatie versus inkomsten: De vergoeding van Amro is gestegen terwijl het bedrijf verliesgevend is.

CEO

Amro Albanna (54 yo)

7.8yrs

Tenure

US$519,233

Compensatie

Mr. Amro A. Albanna has been Chief Executive Officer and a Director of Aditxt, Inc. (formerly known as ADiTx Therapeutics, Inc.) since 2017 and serves as its Chairman of the Board and served as its Preside...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Amro Albanna	Co-Founder	7.8yrs	US$519.23k	0.0070% $ 18.4
Shahrokh Shabahang	Co-Founder	7.8yrs	US$358.84k	0.14% $ 372.0
Thomas Farley	Chief Financial Officer	3.1yrs	US$381.45k	0.0015% $ 3.9
Corinne Pankovcin	Chief Mergers & Acquisitions Officer	2.5yrs	US$390.33k	0.0016% $ 4.2
Rowena Albanna	Chief Operating Officer	4.3yrs	geen gegevens	0.0016% $ 4.2
Jennifer Lee	Director of Human Resources	3.8yrs	geen gegevens	geen gegevens
Dolly Tyan	Senior Vice President of Clinical Development – Transplantation	3.8yrs	geen gegevens	geen gegevens
Ge Chen	Senior Vice President of Preclinical Research & Discovery	2.8yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ADTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Amro Albanna	Co-Founder	7.8yrs	US$519.23k	0.0070% $ 18.4
Shahrokh Shabahang	Co-Founder	7.8yrs	US$358.84k	0.14% $ 372.0
Jeffrey Runge	Independent Director	4.3yrs	US$3.86k	0.00011% $ 0.3
Charles Athle Nelson	Independent Director	less than a year	geen gegevens	0.0048% $ 12.6
Brian Brady	Independent Director	5.8yrs	US$15.00k	0.00024% $ 0.6

5.8yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ADTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Aditxt Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Aditxt, Inc., Annual General Meeting, Aug 07, 2024

Aditxt, Inc. Announces Board Changes

Insufficient new directors

Aditxt, Inc. Announces Resignation of Matthew Shatzkes as Chief Legal Officer, General Counsel and Corporate Secretary

Aditxt, Inc., Annual General Meeting, Aug 16, 2023

Aditxt, Inc., Annual General Meeting, Jun 24, 2022

Recent updates

Aditxt, Inc. announced delayed 10-Q filing

Aditxt, Inc. has filed a Follow-on Equity Offering in the amount of $1.197058 million.

Aditxt, Inc. announced that it has received $0.5 million in funding

Aditxt, Inc., Annual General Meeting, Aug 07, 2024

Aditxt, Inc. announced delayed 10-Q filing

Aditxt, Inc. announced that it expects to receive $4.2 million in funding

Aditxt, Inc. announced delayed annual 10-K filing

Aditxt, Inc. announced that it has received $6.000003 million in funding

Aditxt Regains Compliance with Nasdaq Stockholders' Equity Requirement

Aditxt, Inc. (NasdaqCM:ADTX) entered into an agreement and plan of merger to acquire Evofem Biosciences, Inc. (OTCPK:EVFM) from shareholders.

Third quarter 2023 earnings released: US$47.13 loss per share (vs US$211 loss in 3Q 2022)

Aditxt, Inc. Announces Board Changes

Nasdaq Hearings Panel Grants Aditxt an Exception through December 26, 2023 to Allow Aditxt to Complete its Plan to Demonstrate Compliance with the Equity Rule

Aditxt Receives Written Notice from Nasdaq

Aditxt, Inc. announced that it has received $10 million in funding

Aditxt, Inc. announced that it expects to receive $10 million in funding

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$6.42 loss in 2Q 2022)

Insufficient new directors

Aditxt, Inc. Announces Resignation of Matthew Shatzkes as Chief Legal Officer, General Counsel and Corporate Secretary

Aditxt, Inc., Annual General Meeting, Aug 16, 2023

Aditxt Receives Notice from Nasdaq Due to Non-Compliance with Minimum Stockholders Equity Requirement

Aditxt, Inc. Announces Development and Publication of Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection

Aditxt Regains Compliance with Nasdaq Listing Requirements

Aditxt gains on regaining compliance with Nasdaq listing requirements

Aditxt, Inc. has completed a Follow-on Equity Offering.

Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split

Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials

Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate

Aditxt, Inc., Annual General Meeting, Jun 24, 2022

Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron

Aditxt Provides Update on AditxtReprogramming’s Apoptotic DNA Immunotherapy Therapeutic Platform

High number of new directors

Aditx Therapeutics, Inc. Announces Enhancements to Its Aditxtscore for COVID-19

Aditxt adds Lauren Chung to board of directors

Co-Founder exercised options to buy US$60k worth of stock.

Eazy Testing Inc. Becomes AditxtScore™ Channel Partner, to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring with its Walk-In, Concierge, and Pre-Flight Services

New 90-day high: US$4.10

ADiTx Therapeutics, Inc. Appoints Dolly B. Tyan as Senior Vice President of Clinical Development - Transplantation

Aditx Therapeutics, Inc. Announces the Operational Launch of the AditxtScore™ Immune Monitoring Platform

New 90-day high: US$2.61

Aditxt Signs Distribution Agreement with Todos Medical Ltd. for Aditxtscore™ for Covid-19 Immune Monitoring Service

Aditxt, Todos Medical in distribution pact for for COVID-19 immune monitoring

New 90-day high: US$2.39

We Think ADiTx Therapeutics (NASDAQ:ADTX) Can Afford To Drive Business Growth

Aditx Therapeutics, Inc. Appoints Anthony Voorhies as Head of Business Development for AditxtScore

Aditx Therapeutics, Inc. Secures CLIA Certification for AditxtScore™ Laboratory Operations in Richmond, VA, and Plans to Launch AditxtScore™ for COVID-19 as a Lab Developed Test

ADiTx Therapeutics, Inc. has completed a Composite Units Offering in the amount of $9.6 million.

ADiTx Therapeutics, Inc. has completed an IPO in the amount of $11.040012 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd